B型利钠肽（BNP）和N末端B型利钠肽原（NT-proBNP）对新生儿有用吗？
Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?
作者信息
El-Khuffash Afif, Molloy Eleanor J
机构信息
Department of Neonatology, National Maternity Hospital, Holles St, Dublin 2, Ireland.
出版信息
Arch Dis Child Fetal Neonatal Ed. 2007 Jul;92(4):F320-4. doi: 10.1136/adc.2006.106039.
Abstract
B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NTpBNP) have a major role in screening and diagnosis of cardiac disease and monitoring of the treatment response in children and adults. This review discusses the evidence underpinning the potential benefits of these natriuretic peptides in neonatology. They may serve as a useful adjunct to echocardiography in the diagnosis of patent ductus arteriosus and its response to treatment and the diagnosis of persistent pulmonary hypertension of the newborn. However, more work is needed to explore the possible roles of BNP/NTpBNP in the management of sepsis and monitoring of cardiac performance in neonates.
摘要
B型利钠肽（BNP）和N末端B型利钠肽原（NT-proBNP）在儿童和成人心脏病的筛查、诊断以及治疗反应监测中发挥着重要作用。本综述讨论了这些利钠肽在新生儿科潜在益处的相关证据。它们可作为超声心动图的有益辅助手段，用于诊断动脉导管未闭及其治疗反应，以及诊断新生儿持续性肺动脉高压。然而，需要开展更多工作来探索BNP/NT-proBNP在新生儿脓毒症管理和心脏功能监测中的可能作用。
相似文献
1
Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?
Arch Dis Child Fetal Neonatal Ed. 2007 Jul;92(4):F320-4. doi: 10.1136/adc.2006.106039.
2
B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants.
Acta Paediatr. 2015 Apr;104(4):e139-42. doi: 10.1111/apa.12892. Epub 2015 Feb 4.
3
Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review.
Pediatrics. 2015 Feb;135(2):e510-25. doi: 10.1542/peds.2014-1995. Epub 2015 Jan 19.
4
Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants.
Arch Dis Child Fetal Neonatal Ed. 2011 Mar;96(2):F133-7. doi: 10.1136/adc.2010.185967. Epub 2010 Nov 11.
5
N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
Arch Dis Child Fetal Neonatal Ed. 2008 Jul;93(4):F257-60. doi: 10.1136/adc.2007.120691. Epub 2008 Jan 24.
6
Correlation analysis between echocardiographic flow pattern and N-terminal-pro-brain natriuretic peptide for early targeted treatment of patent ductus arteriosus.
J Matern Fetal Neonatal Med. 2014 Nov;27(17):1800-4. doi: 10.3109/14767058.2014.880879. Epub 2014 Feb 3.
7
Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.
Cochrane Database Syst Rev. 2022 Dec 8;12(12):CD013129. doi: 10.1002/14651858.CD013129.pub2.
8
B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.
Eur J Pediatr. 2015 Oct;174(10):1267-75. doi: 10.1007/s00431-015-2619-0. Epub 2015 Aug 23.
9
The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates.
J Pediatr. 2005 Jul;147(1):38-42. doi: 10.1016/j.jpeds.2005.03.040.
10
Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates.
J Perinatol. 2005 Nov;25(11):709-13. doi: 10.1038/sj.jp.7211383.
引用本文的文献
1
Utility of urinary NT-proBNP in congenital diaphragmatic hernia: a prospective pilot study.
Pediatr Res. 2025 Jun;97(7):2305-2311. doi: 10.1038/s41390-024-03600-x. Epub 2024 Oct 16.
2
Navigating Diagnostic and Treatment Challenges of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia.
J Clin Med. 2024 Jun 11;13(12):3417. doi: 10.3390/jcm13123417.
3
Evaluation of Circulating Cardiovascular Biomarker Levels for Early Detection of Congenital Heart Disease in Newborns in Sweden.
JAMA Netw Open. 2020 Dec 1;3(12):e2027561. doi: 10.1001/jamanetworkopen.2020.27561.
4
Serum and Urinary N-Terminal Pro-brain Natriuretic Peptides as Biomarkers for Bronchopulmonary Dysplasia of Preterm Neonates.
Front Pediatr. 2020 Oct 28;8:588738. doi: 10.3389/fped.2020.588738. eCollection 2020.
5
N-terminal pro-brain natriuretic peptide as a biomarker for differentiating cardiac and pulmonary disease in term neonates with respiratory distress.
J Saudi Heart Assoc. 2020 Apr 17;32(1):65-70. doi: 10.37616/2212-5043.1011. eCollection 2020.
6
NOD-like receptor protein 3 and high mobility group box-1 are associated with prognosis of patients with congenital heart disease.
J Int Med Res. 2020 Mar;48(3):300060519884500. doi: 10.1177/0300060519884500. Epub 2019 Dec 18.
7
Cardiovascular Biomarkers in Amniotic Fluid, Umbilical Arterial Blood, Umbilical Venous Blood, and Maternal Blood at Delivery, and Their Reference Values for Full-Term, Singleton, Cesarean Deliveries.
Front Pediatr. 2019 Jul 2;7:271. doi: 10.3389/fped.2019.00271. eCollection 2019.
8
B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study.
BMJ Open. 2018 Oct 17;8(10):e022562. doi: 10.1136/bmjopen-2018-022562.
9
Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus.
Korean J Pediatr. 2016 Apr;59(4):183-9. doi: 10.3345/kjp.2016.59.4.183. Epub 2016 Apr 30.
10
Amino-Terminal proB-Type Natriuretic Peptide Levels in the Umbilical Cord Blood of Neonates Differ According to the Type of Prenatally Diagnosed Congenital Heart Disease.
Pediatr Cardiol. 2015 Dec;36(8):1742-7. doi: 10.1007/s00246-015-1228-z. Epub 2015 Jul 11.
本文引用的文献
1
Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction.
Pediatrics. 2006 Oct;118(4):e1165-8. doi: 10.1542/peds.2006-0569. Epub 2006 Sep 11.
2
Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock.
Shock. 2006 Aug;26(2):134-9. doi: 10.1097/01.shk.0000226266.99960.d0.
3
N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction.
J Pediatr. 2006 Jul;149(1):28-31. doi: 10.1016/j.jpeds.2006.02.038.
4
Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age.
Acta Paediatr. 2006 Jul;95(7):805-9. doi: 10.1080/08035250500466647.
5
Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure.
Circ Res. 2006 Jul 21;99(2):183-90. doi: 10.1161/01.RES.0000232322.06633.d3. Epub 2006 Jun 15.
6
Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure.
Crit Care Med. 2006 Aug;34(8):2140-4. doi: 10.1097/01.CCM.0000229144.97624.90.
7
Impact of cardiac surgery on plasma levels of B-type natriuretic peptide in children with congenital heart disease.
Int J Cardiol. 2007 Jan 18;114(3):339-44. doi: 10.1016/j.ijcard.2006.01.022. Epub 2006 Jun 6.
8
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery.
J Pediatr. 2006 Mar;148(3):372-6. doi: 10.1016/j.jpeds.2005.10.039.
9
B-type natriuretic peptide in paediatric patients with congenital heart disease.
Eur Heart J. 2006 Apr;27(7):861-6. doi: 10.1093/eurheartj/ehi773. Epub 2006 Feb 8.
10
Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals.
Clin Chim Acta. 2006 Apr;366(1-2):304-8. doi: 10.1016/j.cca.2005.11.005. Epub 2005 Dec 19.
Zotero 插件